|
|
|
||
|
|
||
|
||
The Multiple Myeloma Research Foundation (MMRF) was founded in 1998 by twin sisters Karen Andrews and Kathy Giusti following Kathy's diagnosis with multiple myeloma. Today, the MMRF is the world's number one private funder of myeloma specific research.
To learn more about the MMRF's founding, read our articles in:
• The New York Times
• Family Circle
• Pharmaceutical Executive
• Worth Magazine
To date, the MMRF has raised more than $60 million to fund 51 laboratories worldwide. As good stewards of your funds, the MMRF is proud to channel 92% of dollars raised into supporting the most cutting-edge myeloma research worldwide.
Our tremendous investment has already resulted in significant advances in the field of myeloma, including pivotal research that contributed to the recent approval Velcade, the first myeloma drug in more than a decade. Currently, the MMRF is funding 20 new therapies now in Phase I, II, and III clinical trials - such as Revlimid - that have shown promise in treating myeloma patients at all stages of disease.
We are certain that our efforts to fund the world's most cutting-edge myeloma research will result not only in the development of treatment options, but will also bring us one step closer to our ultimate goal - a cure.
To learn more about the MMRF's founding, read our articles in:
• The New York Times
• Family Circle
• Pharmaceutical Executive
• Worth Magazine
To date, the MMRF has raised more than $60 million to fund 51 laboratories worldwide. As good stewards of your funds, the MMRF is proud to channel 92% of dollars raised into supporting the most cutting-edge myeloma research worldwide.
Our tremendous investment has already resulted in significant advances in the field of myeloma, including pivotal research that contributed to the recent approval Velcade, the first myeloma drug in more than a decade. Currently, the MMRF is funding 20 new therapies now in Phase I, II, and III clinical trials - such as Revlimid - that have shown promise in treating myeloma patients at all stages of disease.
We are certain that our efforts to fund the world's most cutting-edge myeloma research will result not only in the development of treatment options, but will also bring us one step closer to our ultimate goal - a cure.
|
|
|
|
|
|